NorthStar Medical Radioisotopes and YAP Therapeutics are entering a collaboration agreement to develop and produce radiopharmaceuticals aimed at treating cancer and other chronic diseases, NorthStar announced today.

According to a release, NorthStar will support the development of YAP Therapeutics’ biologic products by supplying the radioisotope non-carrier added actinium-225 (n.c.a. Ac-225) and providing access to its radiopharmaceutical contract development and manufacturing (CDMO) services.

“NorthStar leads in medical radioisotope development and production. This agreement furthers our goal to deliver radiopharmaceuticals to patients,” NorthStar President and CEO Frank Scholz said in a statement. “We are excited to partner with YAP Therapeutics, merging our technology with their biologics to target specific therapies. Our ability to provide key radioisotopes like Ac-225 and CDMO capabilities offers substantial support to YAP Therapeutics.”

The agreement also guarantees that YAP Therapeutics, which is located in Laguna Hills, Calif., will receive clinical trial-ready doses of its novel products in development.